Merck KGaA (MRK) Given a €100.00 Price Target at JPMorgan Chase & Co.

Share on StockTwits

Merck KGaA (FRA:MRK) has been given a €100.00 ($116.28) price objective by stock analysts at JPMorgan Chase & Co. in a report issued on Tuesday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 4.49% from the stock’s current price.

A number of other brokerages have also recently commented on MRK. Deutsche Bank set a €93.00 ($108.14) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Tuesday, October 30th. Kepler Capital Markets set a €108.00 ($125.58) price target on shares of Merck KGaA and gave the company a “buy” rating in a research report on Wednesday, December 12th. Sanford C. Bernstein set a €105.00 ($122.09) price target on shares of Merck KGaA and gave the company a “buy” rating in a research report on Tuesday, February 5th. Morgan Stanley set a €88.00 ($102.33) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Friday, December 14th. Finally, Commerzbank set a €100.00 ($116.28) price target on shares of Merck KGaA and gave the company a “buy” rating in a research report on Thursday, November 8th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of €98.80 ($114.88).

Shares of MRK opened at €95.70 ($111.28) on Tuesday. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Further Reading: Is it better to buy a fund with a higher or lower NAV?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply